Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.68 | N/A | +43.30% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.68 | N/A | +43.30% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding market conditions. They are committed to maintaining their strategic initiatives.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term growth despite short-term volatility.
United Therapeutics reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 3.36% in reaction, likely due to a lack of revenue data and no forward guidance. Investors may be concerned about the company's future performance amidst market challenges.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TENET HEALTHCARE COR
Feb 22, 2016